Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Arrowhead Pharmaceuticals Inc. (ARWR)

NASDAQ: ARWR · Pharmaceutical Preparations · Pasadena, CA

Our rating: Neutral

Call changed from Cautious to Neutral at $47.78, moderate conviction, November 13, 2026.

Breaks if: Turn Positive if Arrowhead reports at least $200M in revenue in any single quarter over the next four quarters without a disclosed one-time payment, implying a sustainable royalty or milestone cadence is developing. Turn Cautious if trailing free cash flow turns negative for two consecutive quarters and revenue normalizes below $80M on an annualized basis, signaling the licensing windfall has cleared without a durable replacement taking its place.

Key figures

Market value$5.8B
Revenue, last 12 months$451M
Net income, last 12 months−$724M
Free cash flow, last 12 months−$284M
Price to earningsn/a
Free cash flow yield−4.9%
Dividend yield0.0%
Operating margin−156.9%
Return on equity−280.5%
Beta to the S&P 5001.54
Volatility, annualized64.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$38M−85.3%$-3.01−$196M
June 30, 2026$75M171.0%$-1.36−$181M
March 31, 2026$74M−86.4%$-0.93$82M
December 31, 2025$264M10461.3%$0.22$11M
September 30, 2025$256Mn/a$-0.18$13M
June 30, 2025$28Mn/a$-1.26−$157M
March 31, 2025$543Mn/a$2.75$455M
December 31, 2024$3M−29.6%$-1.39−$154M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

27 ledger entries and 72 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.